Nothing Special   »   [go: up one dir, main page]

SE0300480D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0300480D0
SE0300480D0 SE0300480A SE0300480A SE0300480D0 SE 0300480 D0 SE0300480 D0 SE 0300480D0 SE 0300480 A SE0300480 A SE 0300480A SE 0300480 A SE0300480 A SE 0300480A SE 0300480 D0 SE0300480 D0 SE 0300480D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
pharmaceutical compositions
therapy
preparing
Prior art date
Application number
SE0300480A
Other languages
English (en)
Swedish (sv)
Inventor
Moya Caffrey
Rhonan Ford
Austen Pimm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0300480A priority Critical patent/SE0300480D0/xx
Publication of SE0300480D0 publication Critical patent/SE0300480D0/xx
Priority to MXPA05008690A priority patent/MXPA05008690A/es
Priority to US10/546,131 priority patent/US7227038B2/en
Priority to CNB2004800047676A priority patent/CN100378047C/zh
Priority to PCT/SE2004/000227 priority patent/WO2004074224A1/en
Priority to BRPI0407734-2A priority patent/BRPI0407734A/pt
Priority to CA002515434A priority patent/CA2515434A1/en
Priority to KR1020057015302A priority patent/KR20050101559A/ko
Priority to PL378574A priority patent/PL378574A1/pl
Priority to EP04712798A priority patent/EP1599432A1/en
Priority to JP2006502807A priority patent/JP2006518376A/ja
Priority to AU2004213356A priority patent/AU2004213356B2/en
Priority to RU2005123802/04A priority patent/RU2005123802A/ru
Priority to IL169818A priority patent/IL169818A0/en
Priority to CO05076011A priority patent/CO5580815A2/es
Priority to ZA200506579A priority patent/ZA200506579B/en
Priority to IS8024A priority patent/IS8024A/is
Priority to NO20054329A priority patent/NO20054329L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
    • C07C13/605—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system
    • C07C13/615—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system with an adamantane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0300480A 2003-02-21 2003-02-21 Novel compounds SE0300480D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0300480A SE0300480D0 (sv) 2003-02-21 2003-02-21 Novel compounds
RU2005123802/04A RU2005123802A (ru) 2003-02-21 2004-02-19 Производные адамантана, способы их получения и содержащие их фармацевтические композиции
PL378574A PL378574A1 (pl) 2003-02-21 2004-02-19 Pochodne adamantanu, sposoby ich wytwarzania i zawierające je środki farmaceutyczne
JP2006502807A JP2006518376A (ja) 2003-02-21 2004-02-19 アダマンタン誘導体、その製造方法、それらを含む医薬組成物
CNB2004800047676A CN100378047C (zh) 2003-02-21 2004-02-19 金刚烷衍生物,其制备方法和包含所述衍生物的药物组合物
PCT/SE2004/000227 WO2004074224A1 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
BRPI0407734-2A BRPI0407734A (pt) 2003-02-21 2004-02-19 derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
CA002515434A CA2515434A1 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
KR1020057015302A KR20050101559A (ko) 2003-02-21 2004-02-19 아다만탄 유도체, 이의 제조 방법 및 이를 함유하는 제약조성물
MXPA05008690A MXPA05008690A (es) 2003-02-21 2004-02-19 Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
EP04712798A EP1599432A1 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
US10/546,131 US7227038B2 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
AU2004213356A AU2004213356B2 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
IL169818A IL169818A0 (en) 2003-02-21 2005-07-21 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
CO05076011A CO5580815A2 (es) 2003-02-21 2005-08-02 Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
ZA200506579A ZA200506579B (en) 2003-02-21 2005-08-17 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
IS8024A IS8024A (is) 2003-02-21 2005-09-14 Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær
NO20054329A NO20054329L (no) 2003-02-21 2005-09-20 Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300480A SE0300480D0 (sv) 2003-02-21 2003-02-21 Novel compounds

Publications (1)

Publication Number Publication Date
SE0300480D0 true SE0300480D0 (sv) 2003-02-21

Family

ID=20290476

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300480A SE0300480D0 (sv) 2003-02-21 2003-02-21 Novel compounds

Country Status (18)

Country Link
US (1) US7227038B2 (is)
EP (1) EP1599432A1 (is)
JP (1) JP2006518376A (is)
KR (1) KR20050101559A (is)
CN (1) CN100378047C (is)
AU (1) AU2004213356B2 (is)
BR (1) BRPI0407734A (is)
CA (1) CA2515434A1 (is)
CO (1) CO5580815A2 (is)
IL (1) IL169818A0 (is)
IS (1) IS8024A (is)
MX (1) MXPA05008690A (is)
NO (1) NO20054329L (is)
PL (1) PL378574A1 (is)
RU (1) RU2005123802A (is)
SE (1) SE0300480D0 (is)
WO (1) WO2004074224A1 (is)
ZA (1) ZA200506579B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
CA2526883A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha.
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
JP4936897B2 (ja) 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
WO2007008155A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 1
ES2569428T3 (es) 2006-07-13 2016-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina como MTKI
TW200819416A (en) * 2006-09-05 2008-05-01 Astrazeneca Ab Novel process 470
JP5536647B2 (ja) 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロロピリミジン
DK2105164T3 (da) 2008-03-25 2011-03-21 Affectis Pharmaceuticals Ag Nye P2X7R-antagonister og deres anvendelse
KR20100053150A (ko) * 2008-11-12 2010-05-20 한국생명공학연구원 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (zh) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
PL2804865T3 (pl) 2012-01-20 2016-06-30 Idorsia Pharmaceuticals Ltd Heterocykliczne pochodne amidowe jako antagoniści receptora p2x7
ES2622372T3 (es) * 2012-11-09 2017-07-06 Scidose Llc Composición de enema para tratamiento de la colitis ulcerosa que tiene estabilidad a largo plazo
JP6295269B2 (ja) 2012-12-12 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
WO2014115072A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
SG52229A1 (en) 1993-08-10 1998-09-28 Black James Foundation Gastrin and cck receptor ligands
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
BR0009651A (pt) 1999-04-09 2002-01-08 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
CZ20042A3 (en) 2001-07-02 2004-04-14 Akzo Nobel N. V. Tetrahydroquinoline derivatives
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) 2003-02-18 2003-02-18 Astrazeneca Ab New combination
WO2004105796A1 (en) 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
CA2526883A1 (en) 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha.
US20070010497A1 (en) 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
NO20054329D0 (no) 2005-09-20
US7227038B2 (en) 2007-06-05
CN100378047C (zh) 2008-04-02
WO2004074224A1 (en) 2004-09-02
ZA200506579B (en) 2006-05-31
AU2004213356A1 (en) 2004-09-02
CA2515434A1 (en) 2004-09-02
PL378574A1 (pl) 2006-05-02
KR20050101559A (ko) 2005-10-24
IS8024A (is) 2005-09-14
EP1599432A1 (en) 2005-11-30
NO20054329L (no) 2005-11-21
IL169818A0 (en) 2007-07-04
AU2004213356B2 (en) 2007-03-15
CN1751010A (zh) 2006-03-22
MXPA05008690A (es) 2005-10-05
BRPI0407734A (pt) 2006-02-14
JP2006518376A (ja) 2006-08-10
US20060160904A1 (en) 2006-07-20
CO5580815A2 (es) 2005-11-30
RU2005123802A (ru) 2006-02-27

Similar Documents

Publication Publication Date Title
SE0300480D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
SE0200920D0 (sv) Novel compounds
SE0103836D0 (sv) Novel compounds
SE0202539D0 (sv) Compounds
SE0302811D0 (sv) Novel compounds
IS6658A (is) Ný efnasambönd
ATE316083T1 (de) Adamantanderivate
SE0301700D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
HK1048990A1 (en) Novel compounds.
TW200613243A (en) Novel compounds
MY128924A (en) Novel compounds
DE602004021472D1 (en) Pyrimiidinverbindungen
SE0300119D0 (sv) Novel compounds
SE0401762D0 (sv) Novel compounds
SE0302192D0 (sv) Novel compounds
TW200604197A (en) New compounds
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
TW200740781A (en) Novel compounds
SE0402925D0 (sv) Novel Compounds
SE0101038D0 (sv) Novel compounds
SE0401763D0 (sv) Compounds
GB0120461D0 (en) Novel compounds
SE0303280D0 (sv) Novel compounds